Evidence map›Paper›PMID 34950216›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2021

Shu-Di-Huang and Gan-Cao Herb Pair Restored the Differentiation Potentials of Mesenchymal Stem Progenitors in Treating Osteoporosis via Downregulation of NF-

Xiaopeng Ling, Xiaojian Wang, Jinghu Li, Taiwei Zhang, Xing Zhou, Yiyuan Zhou, Jian Kang

Open access · hybridAbstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Effectiveness ofFrontiers in endocrinology · 2022
    Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 1 country.

Xiaopeng LingDepartment of Orthopaedics, The Fourth Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.ORCID https://orcid.org/0000-0002-2661-134X
Xiaojian WangThe First Clinical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.ORCID https://orcid.org/0000-0002-0618-3309
Jinghu LiDepartment of Tuina, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.ORCID https://orcid.org/0000-0001-6322-7382
Taiwei ZhangObstetrics Department, The First Affiliated Hospital of Guizhou University of Chinese Medicine, Guiyang, Guizhou, China.ORCID https://orcid.org/0000-0003-4440-419X
Xing ZhouDepartment of Orthopaedics, Shanghi University of Traditional Chinese Medicine Taizhou Hospital, Taizhou, Zhejiang, China.ORCID https://orcid.org/0000-0002-6931-2518
Yiyuan ZhouObstetrics Department, The First Affiliated Hospital of Guizhou University of Chinese Medicine, Guiyang, Guizhou, China.ORCID https://orcid.org/0000-0002-2013-6373
Jian KangDepartment of Orthopaedics, The Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.ORCID https://orcid.org/0000-0002-3388-6026
Affiliated Hospital of Guizhou Medical University · CNJiangxi University of Traditional Chinese Medicine · CNNanchang University · CNThe Third Affiliated Hospital of Zhejiang Chinese Medical University · CNWenzhou Medical University · CNZhejiang Chinese Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundShu-Di-Huang (Radix Rehmanniae Praeparata, RR) and Gan-Cao (liquorice, L) are frequently used traditional Chinese herb pair in treating osteoporosis (OP). However, the exact mechanism of the RR and L herb pair (RR-L) remains unclear. To explore the efficacy and possible mechanisms of RR-L in treating OP, in silico, in vitro, and in vivo experiments were conducted in the current study.

methodsIn silico, potential therapeutic target genes and active chemical compounds of RR-L herb pair were predicted and constructed into a network. In vivo, 30 Sprague Dawley rats were divided into 3 groups, including the sham group, the OP model group, and the RR-L-treated OP group. Micro-CT and pathological sections were conducted to validate the therapeutic effects of RR-L in treating OP. MSCs of rats were isolated and cultured in vitro to validate the mesenchymal stem cells (MSCs) related phenotype changes, including Alizarin red staining, Oil red staining, and immunofluorescence. In vitro, cell proliferation analysis, Alizarin red staining, Oil red staining, immunofluorescence of NF-

resultsIn silico, 168 chemical compounds with a property of oral bioavailability ≥30% and drug-likeness ≥0.18 were recognized as potentially active compounds in RR-L and 249 genes were found to be the targets of which. Among them, 120 genes were found to be therapeutic genes of RR-L in treating OP and KEGG and GO analysis of which demonstrated that RR-L involves in lipid metabolism and multiple inflammation-related signaling pathways. In vivo, ovariectomy- (OVX-) induced OP phenotypes in Sprague Dawley rats include bone mineral density and microarchitecture damaging, abnormal bone metabolism, upregulation of inflammation markers, and damaged differentiation potential of MSCs. Treatment of RR-L reversed the trend and restored the differentiation potential of MSCs. In vitro, RR-L containing serum promoted the osteogenic differentiation and suppressed adipogenic differentiation of MSCs via downregulation of the NF-

conclusionsIn the current study, network pharmacology prediction and experimental validation elucidated that the RR-L herb pair restored damaged MSC differentiation potential via the NF-

Identifiers

PMID34950216
PMCPMC8692010
OpenAlexW4200023537

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.